SS Innovations International

SSII

Market cap $1.21B

— Submission covers multiple indications including general, urological, colorectal, gynecological and cardiac surgeries — SS Innovations has officially submitted a 510(k) application to the U.S. FDA for its SSi Mantra surgical robotic system, aiming for clearance to enter the U.S. market.

-- Submission covers multiple indications including general, urological, colorectal, gynecological and cardiac surgeries -- FORT LAUDERDALE, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (the “FDA”) on December 5, 2025, for the SSi Mantra surgical robotic system for multiple specialty procedure types, including: general, urological, colorectal, gynecological, and cardiac surgery.

Recent sell-offs have created entry points in warehouse automation, satellite connectivity, and robotic surgery. These companies serve non-cyclical markets with multibillion-dollar addressable opportunities and contracted revenue visibility.

Compact New Console Facilitates Performance of Telesurgeries from a Wide Range of Locations, including Physicians' Offices Key Takeaways Historic First for Robotic TelesurgerySS Innovations (Nasdaq: SSII) successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), enabling remote operations from any connected location.

FORT LAUDERDALE, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful completion of the first telesurgery performed with the Company's SSi Mantra Tele Surgeon Console (the “TSC”).

Quarterly Revenue Increased 192.5% Year over Year to $12.8 Million Driven by Higher SSi Mantra 3 Unit Sales Fort Lauderdale, FL, October 28, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – SS Innovations International, Inc.

FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and nine months ended September 30, 2025.

Fort Lauderdale, FL, October 21, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that Dr.

FORT LAUDERDALE, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia Pacific, are scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference Palm Beach Gardens, FLTuesday, November 11, 2025Management will be available for one-on-one and small group meetings throughout the day.

Investing in emerging technologies is never for the faint of heart. These companies often trade more on potential than on current results, making them volatile and unpredictable.